Startup Funding News

Connecta Therapeutics develops small-molecule treatments for neurological disorders, including CTH120, a clinical-stage candidate for Fragile X syndrome.

Single-cell tumour profiling for oncology teams and pharma and biotech partners, turning routine biopsy samples into clinical insights for treatment selection and drug development.

A phage-discovery and development company that uses bacteriophage libraries, bioinformatics and machine learning to identify targeted solutions against bacterial strains.

Allogenetics is developing a one-time ex vivo gene therapy that modifies donor organs before transplantation, aiming to reduce immune rejection without suppressing the recipient’s immune system. Its lead ALG-115 program is advancing through preclinical and IND-enabling work for lung transplantation.

A peptide-targeting platform is advancing conjugate and radioligand therapies for solid tumors.

A biotechnology startup developing numerical representations of three-dimensional molecules for AI-assisted drug and chemical research.

A clinical-stage immunotherapy company is advancing an engineered CTLA-4 antibody for earlier cancer treatment.

A non-viral nanovesicle platform targets delivery of genetic medicines to specific cells and tissues.

Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.

Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027.